Suven Life Sciences to showcase its Differentiated CNS Clinical Candidates and Partnering Strategies at BIO International Convention 2026, 22-25, June 2026, San Diego, USA

Suven Life Sciences Limited a clinical-stage biopharmaceutical company focused on discovering and developing innovative treatments for Central Nervous System (CNS) disorders, today announced its participation in the BIO International Convention 2026 (BIO-2026), one of the world's largest Biotechnology Partnering Conferences, taking place during June 22-25, 2026, in San Diego, USA.

Suven Life Sciences will welcome the Delegates, Investors, and Potential Partners & collaborators from Big Pharma, Biotech companies to Booth # 6154, where the company will showcase its Differentiated CNS portfolio, including late-stage clinical assets targeting significant unmet medical needs in indications like Agitation in Dementia of Alzheimer's Type, Major Depressive Disorder, Narcolepsy, Cognitive Impairment associated with Parkinson's disease and other CNS disorders.

The goal is to engage with global pharmaceutical and biotechnology companies to explore partnering strategies, out-licensing, and/or co-development initiatives for Suven clinical candidates through 62 pre-scheduled partnering meetings in 4 days of BIO-2026.

The Suven delegation at BIO-2026 includes senior leaders from Management team and Research:

Venkat Jasti, Chairman and Managing Director
Ramakrishna Nirogi, President and Chief Scientific Officer.
Anil Shinde, Vice President, Drug Chemistry.
Pradeep Jayarajan, Vice President, Drug Biology.
Vijay Benade, Associate Vice President, Drug Metabolism & Pharmacokinetics.
Satish Jetta, Associate Vice President, Quality Assurance & Regulatory.

"BIO-2026 offers a valuable opportunity to highlight the meaningful advancements across our clinical pipeline and connect with potential partners who share our dedication to addressing unmet needs in CNS disorders. The positive Phase 2b results for Ropanicant in major depressive disorder, promising and favaurble Phase-1 data for SUVN-I6107, continued progress of our Phase-3 programs, Masupirdine for agitation in dementia of Alzheimer's type and Samelisant (AWAKE study) for narcolepsy, underscore the depth and maturity of our portfolio. We look forward to exploring strategic partnering and collaboration opportunities that can help accelerate the development and commercialization of these assets," said Mr. Venkat Jasti, Chairman and Managing Director of Suven Life Sciences.

Shares of Suven Life Sciences Limited was last trading in BSE at Rs. 265.35 as compared to the previous close of Rs. 268.15. The total number of shares traded during the day was 49631 in over 1141 trades.

The stock hit an intraday high of Rs. 277.00 and intraday low of 263.05. The net turnover during the day was Rs. 13339077.00.

Source : Equity Bulls

Keywords

SuvenLifeSciences INE495B01038 Pharmaceuticals